Guangdong Zhongsheng Pharmaceutical Co Ltd (SHE:002317) — Market Cap & Net Worth
Market Cap & Net Worth: Guangdong Zhongsheng Pharmaceutical Co Ltd (002317)
Guangdong Zhongsheng Pharmaceutical Co Ltd (SHE:002317) has a market capitalization of $2.29 Billion (CN¥15.63 Billion) as of May 4, 2026. Listed on the SHE stock exchange, this China-based company holds position #5784 globally and #1208 in its home market, demonstrating a 0.22% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Guangdong Zhongsheng Pharmaceutical Co Ltd's stock price CN¥18.39 by its total outstanding shares 849930477 (849.93 Million). Analyse 002317 cash flow conversion to see how efficiently the company converts income to cash.
Guangdong Zhongsheng Pharmaceutical Co Ltd Market Cap History: 2015 to 2026
Guangdong Zhongsheng Pharmaceutical Co Ltd's market capitalization history from 2015 to 2026. Data shows growth from $1.43 Billion to $2.29 Billion (5.41% CAGR).
Guangdong Zhongsheng Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Guangdong Zhongsheng Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.61x
Guangdong Zhongsheng Pharmaceutical Co Ltd's market cap is 0.61 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.43 Billion | $1.58 Billion | $296.71 Million | 0.90x | 4.81x |
| 2016 | $1.35 Billion | $1.69 Billion | $414.37 Million | 0.80x | 3.25x |
| 2017 | $1.40 Billion | $1.96 Billion | $420.12 Million | 0.72x | 3.34x |
| 2018 | $938.53 Million | $2.36 Billion | $435.65 Million | 0.40x | 2.15x |
| 2019 | $1.46 Billion | $2.53 Billion | $317.73 Million | 0.58x | 4.60x |
| 2020 | $1.29 Billion | $1.90 Billion | -$426.61 Million | 0.68x | N/A |
| 2021 | $1.45 Billion | $2.43 Billion | $277.63 Million | 0.60x | 5.21x |
| 2022 | $3.27 Billion | $2.68 Billion | $322.05 Million | 1.22x | 10.16x |
| 2023 | $1.97 Billion | $2.61 Billion | $263.27 Million | 0.75x | 7.48x |
| 2024 | $1.51 Billion | $2.47 Billion | -$299.16 Million | 0.61x | N/A |
Competitor Companies of 002317 by Market Capitalization
Companies near Guangdong Zhongsheng Pharmaceutical Co Ltd in the global market cap rankings as of May 4, 2026.
Key companies related to Guangdong Zhongsheng Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.15 |
Guangdong Zhongsheng Pharmaceutical Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Guangdong Zhongsheng Pharmaceutical Co Ltd's market cap moved from $1.43 Billion to $ 2.29 Billion, with a yearly change of 5.41%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥2.29 Billion | -3.11% |
| 2025 | CN¥2.36 Billion | +56.21% |
| 2024 | CN¥1.51 Billion | -23.23% |
| 2023 | CN¥1.97 Billion | -39.81% |
| 2022 | CN¥3.27 Billion | +126.02% |
| 2021 | CN¥1.45 Billion | +12.20% |
| 2020 | CN¥1.29 Billion | -11.75% |
| 2019 | CN¥1.46 Billion | +55.72% |
| 2018 | CN¥938.53 Million | -33.19% |
| 2017 | CN¥1.40 Billion | +4.30% |
| 2016 | CN¥1.35 Billion | -5.55% |
| 2015 | CN¥1.43 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Guangdong Zhongsheng Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.29 Billion USD |
| MoneyControl | $2.29 Billion USD |
| MarketWatch | $2.29 Billion USD |
| marketcap.company | $2.29 Billion USD |
| Reuters | $2.29 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Guangdong Zhongsheng Pharmaceutical Co Ltd
Guangdong Zhongsheng Pharmaceutical Co., Ltd. engages in research, development, production, and sale of pharmaceutical drugs in China. The company offers traditional Chinese medicine and chemical medicine. It also focuses on the fields of cardiovascular, respiratory, ophthalmology, and digestive. Guangdong Zhongsheng Pharmaceutical Co., Ltd. was founded in 1979 and is based in Dongguan, China.